Pioneering Medical Innovations
Sentinel System Shown to Protect the Vast Majority of Brain Regions from Risk of Cerebral Infarcts; Reduces Number and Volume of
FDA clearance in hand, Augmenix is formulating U.S. commercial sales and insurance reimbursement plans for a medical gel designed to
First-of-its-kind Treatment Offers Significant Clinical Benefits to Prostate Cancer Patients Undergoing Radiotherapy WALTHAM, Mass.—April 2, 2015—Augmenix, Inc., a privately held
— Topline results of the second Phase 3 clinical trial expected by the end of March — — NDA submission
OTX-DP Demonstrated Statistically Significant Therapeutic Effect for Ocular Itching and Conjunctival Redness over Six Weeks with a Single Dose BEDFORD,
Clinical Trial is First to Definitively Demonstrate That Removing Embolic Debris from Cerebral Circulation Can Significantly Shield the Brain TCT
Teleflex Incorporated (Limerick, PA) announced that it has received CE Mark approval to market the company’s Arrow GPSCath balloon dilatation
PLEASANTON, Calif., May 23, 2012 /PRNewswire/ — TriReme Medical, Inc. (TMI) today announced approval by the U.S. Food and Drug
Study will evaluate reduction in intraocular pressure and product retention. Ocular Therapeutix, Inc. announced today the commencement of a sustained
Ocular Therapeutix, Inc. announced today that it has received IDE approval from the U.S. Food and Drug Administration to conduct